What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

Lilly's already holding its own in immunology with Taltz, which made nearly $3.3 billion in sales last year. Omvoh could carve a niche for itself in the Crohn's disease market. Ebglyss should also ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

such as for the drug Omvoh for Crohn's disease and Ebglyss for atopic dermatitis, further resulted in positive sentiment. These concerted efforts support Eli Lilly's robust performance ...

These include Kisunla in Alzheimer's disease; Ebglyss, an eczema treatment; and ulcerative colitis therapy Omvoh. Further, Eli Lilly has an incredibly deep pipeline. Yes, here too, the company's ...